Cargando…
Intranasal parainfluenza virus type 5 (PIV5)–vectored RSV vaccine is safe and immunogenic in healthy adults in a phase 1 clinical study
Respiratory syncytial virus (RSV) can lead to serious disease in infants, and no approved RSV vaccine is available for infants. This first in-human clinical trial evaluated a single dose of BLB201, a PIV5-vectored RSV vaccine administrated via intranasal route, for safety and immunogenicity in RSV-s...
Autores principales: | Spearman, Paul, Jin, Hong, Knopp, Kristeene, Xiao, Peng, Gingerich, Maria Cristina, Kidd, Jamie, Singh, Karnail, Tellier, Marinka, Radziewicz, Henry, Wu, Samuel, McGregor, Matthew, Freda, Barbara, Wang, Zhaoti, John, Susan P., Villinger, Francois J., He, Biao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599610/ https://www.ncbi.nlm.nih.gov/pubmed/37878713 http://dx.doi.org/10.1126/sciadv.adj7611 |
Ejemplares similares
-
A parainfluenza virus 5 (PIV5)-vectored intranasal vaccine for Lyme disease provides long-lasting protection against tick transmitted Borrelia burgdorferi in mice
por: Gingerich, Maria Cristina, et al.
Publicado: (2023) -
Structure of the Parainfluenza Virus 5 (PIV5) Hemagglutinin-Neuraminidase (HN) Ectodomain
por: Welch, Brett D., et al.
Publicado: (2013) -
Efficacy of Parainfluenza Virus 5 (PIV5)-vectored Intranasal COVID-19 Vaccine as a Single Dose Vaccine and as a Booster against SARS-CoV-2 Variants
por: Beavis, Ashley C., et al.
Publicado: (2022) -
Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates
por: Xiao, Peng, et al.
Publicado: (2021) -
Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
por: Baldeon Vaca, Gabriela, et al.
Publicado: (2023)